Apidra® (insuline glulisine)

Apidra® is an analog of human insulin produced by fast acting genetical engineering.

Apidra® is indicated for the treatment of adults with type 1 and in type 2 diabetes for supplementary glycemic control. Apidra® has a more rapid onset and shorter duration of action than fast-acting human insulin and can be associated with long-acting insulins such as Lantus® for supplementary glycemic control at mealtime.

In addition, Apidra® is equally effective in adult diabetics ranging from lean to obese and offers patients greater flexibility of administration, either before or just after meal.

Apidra® was launched at the beginning of 2005 and is available in several European countries.